

Anant Investments

C/o Apex Fund & Corporate Services (Mauritius) Ltd
Lot 15 A3, 1st Floor, CyberCity, Ebene 72201, Mauritius
Tel: (230) 404 3900 Fax: (230) 454 6824

CONSENT FROM THE SELLING SHAREHOLDER

Date: October 11, 2022

To,

The Board of Directors
Global Health Limited
Medanta – Mediclinic
E-18, Defence Colony
New Delhi – 110024, India

Dear Sir,

Sub: Proposed initial public offering of equity shares (the "Equity Shares") of Global Health Limited (the "Company" and such offer, the "Offer")

We hereby give our consent to the following:

- (i) Inclusion of up to 50,661,000 Equity Shares in the Company as part of the offer for sale in the Offer (the "Offered Shares"), subject to the approval of the Securities and Exchange Board of India ("SEBI"), and of any other regulatory authority, if required.
- (ii) Inclusion of our name as an investor selling shareholder and any other information as required under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "SEBI ICDR Regulations") and other applicable laws in the Red Herring Prospectus and the Prospectus which the Company intends to file with the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi (the "RoC") and thereafter file with SEBI and any relevant stock exchange(s) where the Equity Shares are proposed to be listed (the "Stock Exchanges").

We also authorise you to deliver a copy of this letter of consent to the RoC, pursuant to the provisions of sections 26 and 32 of the Companies Act, 2013, the Stock Exchanges, SEBI or any other statutory or regulatory authority, as required by law. We also consent to the inclusion of this letter as a part of "*Material Contracts and Documents for Inspection*" in connection with the Offer, which will be available to the public for inspection from the date of the filing of the RHP until the Bid/ Offer Closing Date.

We confirm that this consent will remain valid and in force till the date on which Equity Shares of the Company start trading on the Stock Exchanges, in the absence of any written communication from us.

We confirm that the information in this letter is true, correct, and not misleading in any material respect.

We confirm that we will immediately communicate any changes in writing in the above information to the Book Running Lead Managers until the date when the Equity Shares are listed and commence trading on the relevant stock exchanges (the "Stock Exchanges") pursuant to the Offer. In the absence of any such communication from us, the Book Running Lead Managers and the legal advisors to each of the Company and Book Running Lead Managers can assume that there is no change to the above information until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Offer.

This letter is for information and for inclusion (in part or full) in the red herring prospectus ("RHP") and the prospectus ("Prospectus") filed in relation to the Offer (collectively, the "Offer Documents") or any other Offer-related material, and may be relied upon by the Company, the Book Running Lead Managers and the legal advisors appointed by the Company and the Book Running Lead Managers in relation to the Offer. We hereby consent to this letter being disclosed by the Book Running Lead Managers, if required (i) by reason of any law, regulation

Certified True Copy



Anant Investments

C/o Apex Fund & Corporate Services (Mauritius) Ltd
Lot 15 A3, 1st Floor, CyberCity, Ebene 72201, Mauritius
Tel: (230) 404 3900 Fax: (230) 454 6824


or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defence in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation. We hereby consent to the aforementioned details being included in the Offer Documents and submission of this letter as may be necessary, to the SEBI, the Registrar of Companies, the RoC, the Stock Exchanges and any other regulatory or judicial authorities and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law.

All capitalized terms used herein and not defined shall have the same meaning as assigned to them in Offer Documents.

Thanking you

Yours faithfully,

For Anant Investments



Adilah Ibrahim Balladin
Director
Place: Mauritius

Cc:

Kotak Mahindra Capital Company Limited 1st Floor, 27 BKC, Plot No. 27, 'G' Block Bandra Kurla Complex, Bandra (East), Mumbai 400 051 Maharashtra, India	Credit Suisse Securities (India) Private Limited Ceejay House, 10th Floor, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400 018 Maharashtra, India
Jefferies India Private Limited 42/43, 2 North Avenue Maker Maxity, Bandra-Kurla Complex Bandra (East), Mumbai 400 051 Maharashtra, India	JM Financial Limited 7th Floor, Cnergy, AppasahebMaratheMarg, Prabhadevi, Mumbai 400 025
S&R Associates 64, Okhla Industrial Estate Phase III New Delhi 110 020	AZB & Partners AZB House, Peninsula Corporate Park Ganpatrao Kadam Marg, Lower Parel Mumbai 400 013
AZB & Partners AZB House Plot No. A8, Sector-4 Noida 201 301	Saraf and Partners Law Offices One International Centre Tower 2, Unit No 2402, 24th floor Senapati Bapat Marg Lower Parel, Mumbai – 400013, India

Anant Investments
(the "Company")

CERTIFIED EXTRACT OF WRITTEN RESOLUTION DATED SEPTEMBER 13, 2021 PASSED IN LIEU OF HOLDING A MEETING OF DIRECTORS IN ACCORDANCE WITH SECTION 7 OF THE EIGHTH SCHEDULE OF THE COMPANIES ACT 2001.

"INITIAL PUBLIC OFFERING OF GLOBAL HEALTH LIMITED

WHEREAS, it is proposed for the Company to participate in the initial public offering ("IPO") of GLOBAL HEALTH LIMITED ("GHL" or the "Issuer") (the "Issue"), a public limited company incorporated under the Companies Act, 1956, having its registered office at Medanta-Mediclinic E-18, Defence Colony, New Delhi 110 024, India.

WHEREAS, it is noted that the Company owns 65 million equity shares of face value of Rs. 2 each and 466,954 class A preference shares of face value of Rs. 696 each of GHL.

WHEREAS, it is proposed for the Company to consent to participating in the offer for sale in the IPO, subject to the approval of Securities and Exchange Board of India ("SEBI"), and of any other regulatory authority, as applicable.

WHEREAS, pursuant to section 130 of the Mauritius Companies Act 2001 (the "Act"), the shareholders are required to approve any "major transaction" in relation to the Company. A "major transaction" under the Act means the acquisition, disposition or any other transaction involving assets of the company, acquisitions of rights or interests, or the incurrence of obligations or liabilities, the value of which is more than 75 per cent of the value of the company's assets before the transaction.

WHEREAS, the Company's participation in the IPO of the Issuer qualifies as a "major transaction" under the Act.

WHEREAS, pursuant to section 130 of the Act, the shareholder of the Company approved the entry into of the IPO and the Transaction Documents (as defined in paragraph B below), as per the written resolution of the shareholder of the Company dated September 13 2021, a copy of which is attached as Annex 1 to this written Board resolution.

After due consideration, **NOW, THEREFORE, BE IT RESOLVED THAT:**


- A. the Company's participation in the proposed initial public offering of equity shares of face value of Rs. 2 each of GLOBAL HEALTH LIMITED (the "Issue" and such equity shares the "Equity Shares") by way of an offer for sale of up to 100% of our shareholding in the Issuer in the IPO, aggregating up to 65 million Equity Shares along with such number of equity shares as may be received by us pursuant to conversion of the 466,954 Class A Preference Shares of the Issuer that are held by us, subject to receiving our investment committee's approval in this regard, and subject to such flexibility as may be permitted under applicable law, and further subject to pricing, timing and other issue related considerations, in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, the Companies Act, 2013, as amended, including rules made thereunder and other applicable laws be, and is hereby, approved;
- B. the (i) contents of: (a) the draft red herring prospectus, (b) the red herring prospectus and (c) the prospectus (collectively the "Offer Documents") (only to the extent of statements and undertakings made by the Company therein about or in relation to itself as a selling shareholder and its portion of the Equity Shares being offered by the Company in the offer for sale), (ii) the consent letter and the certificate to be issued by the Company as a selling shareholder in the Issue, (iii) the offer agreement to be executed by and amongst the Company, the Issuer, the book running lead managers to the Offer (the "BRLMs") and other selling shareholders (the Offer Agreement"); (iv) the common engagement letter with the Issuer, the BRLMs and other selling shareholders; (v) the registrar agreement to be entered into with the registrar, the Issuer and other selling shareholders (the "Registrar Agreement"); (vi) the underwriting agreement to be executed by and amongst the underwriter, the Issuer, the Company, the other selling shareholders and certain other parties (the "Underwriting Agreement"); (vii) the cash escrow and sponsor bank agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the "Cash Escrow and Sponsor Bank Agreement"); (viii) the share escrow agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the

"Share Escrow Agreement"); (ix) the syndicate agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the "Syndicate Agreement"); and (x) any other document, including a consent letter for variations of the terms of the Class A Preference Shares held by us, or agreement to be executed in relation to the Issue (collectively, the "Transaction Documents"), be and are hereby approved;

- C. any one of Mrs. Adiliah Ibrahim Balladin or Messrs. Santosh Gujadhur or Tej K. Gujadhur be authorised to: (i) determine the number of Equity Shares that will be offered by the Company in the offer for sale or the aggregate amount to be raised by the Company through its participation in the offer for sale in the IPO, (ii) negotiate, finalise, execute, sign and deliver in the name and on behalf of the Company: (a) the Transaction Documents, substantially in the form approved or with such amendments as may be deemed necessary or desirable; and (b) any other related documents, offer documents (including the red herring prospectus and prospectus), deeds, consent letter, certificates, contracts, arrangements, and/ or ancillary documents, in relation thereto; (iii) finalise the offer price, the price band, discount (if any), the anchor allocation and any other offer terms in relation to the Issue, along with the Issuer in consultation with the book running lead managers appointed for the Issue and (iv) take all actions as may be required or necessary in the context of the Issue and any other matters in connection therewith;
- D. any and all actions of the Company, or of any director or officer or advisor, taken in connection with the actions contemplated by the foregoing prior to the execution hereof be ratified, confirmed, approved and adopted in all respects as fully as if such action(s) had been presented for approval, and approved by, all directors prior to such action being taken; and
- E. in connection with the actions contemplated by the foregoing resolutions, each of the directors, officers and any attorney or authorised signatory and such other person as were authorised by any of them be authorised, in the name and on behalf of the Company, to do such further acts and things as any director or officer or such duly authorised other person shall deem necessary or appropriate in connection with, or to carry out the actions contemplated by, the foregoing resolutions, including to do and perform (or cause to be done and performed), in the name and on behalf of the Company, all such acts and to make, execute, deliver, issue or file (or cause to be made, delivered, or filed) with any person including any governmental authority or agency, all such agreements, documents, instruments, certificates, consents and waivers, and all amendments to any such agreement, documents, instruments, certificates, and to pay, or cause to be paid, all such payments, as any of them may deem necessary or advisable to carry out the intent of the foregoing resolutions, the authority for the taking of any such action and the execution and delivery of such of the foregoing to be conclusively evidenced hereby."

IT IS HEREBY CERTIFIED THAT the above are true and correct extracts from the board resolutions of the Company held on the date first mentioned above.

Dated this September 24, 2021



Adiliah Ibrahim Balladin
For Apex Fund & Corporate Services (Mauritius) Ltd
Company Secretary

**Anant Investments
(the "Company")**

CERTIFIED EXTRACT OF WRITTEN RESOLUTION DATED SEPTEMBER 13, 2021 PASSED IN LIEU OF
HOLDING A SPECIAL MEETING IN ACCORDANCE WITH SECTION 117 OF THE COMPANIES ACT 2001.

"INITIAL PUBLIC OFFERING OF GLOBAL HEALTH LIMITED

WHEREAS, it is proposed for the Company to participate in the initial public offering ("IPO") of GLOBAL HEALTH LIMITED ("GHL" or the "Issuer") (the "Issue"), a public limited company incorporated under the Companies Act, 1956, having its registered office at Medanta-Mediclinic E-18, Defence Colony, New Delhi 110 024, India.

WHEREAS, it is noted that the Company owns 65 million equity shares of face value of Rs. 2 each and 466,954 class A preference shares of face value of Rs. 696 each of GHL.

WHEREAS, it is proposed for the Company to consent to participating in the offer for sale in the IPO, subject to the approval of Securities and Exchange Board of India ("SEBI"), and of any other regulatory authority, as applicable.

WHEREAS, pursuant to section 130 of the Mauritius Companies Act 2001 (the "Act"), the shareholders are required to approve any "major transaction" in relation to the Company. A "major transaction" under the Act means the acquisition, disposition or any other transaction involving assets of the company, acquisitions of rights or interests, or the incurrance of obligations or liabilities, the value of which is more than 75 per cent of the value of the company's assets before the transaction.

WHEREAS, the Company's participation in the IPO of the Issuer qualifies as a "major transaction" under the Act.

After due consideration, **NOW, THEREFORE, BE IT RESOLVED THAT:**


- A. the participation in the IPO and the execution of the Transaction Documents, as defined in paragraph C below, qualifying as major transactions contemplated by the Company, be, and hereby are, approved;
- B. the Company's participation in the proposed initial public offering of equity shares of face value of Rs. 2 each of GLOBAL HEALTH LIMITED (the "Issue" and such equity shares the "Equity Shares") by way of an offer for sale of up to 100% of our shareholding in the Issuer in the IPO, aggregating up to 65 million Equity Shares along with such number of equity shares as may be received by us pursuant to conversion of the 466,954 Class A Preference Shares of the Issuer that are held by us, subject to receiving our investment committee's approval in this regard, and subject to such flexibility as may be permitted under applicable law, and further subject to pricing, timing and other Issue related considerations, in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, the Companies Act, 2013, as amended, including rules made thereunder and other applicable laws, be, and is hereby, approved;

- C. the (i) contents of: (a) the draft red herring prospectus, (b) the red herring prospectus and (c) the prospectus (collectively the "Offer Documents") (only to the extent of statements and undertakings made by the Company therein about or in relation to itself as a selling shareholder and its portion of the Equity Shares being offered by the Company in the offer for sale), (ii) the consent letter and the certificate to be issued by the Company as a selling shareholder in the Issue, (iii) the offer agreement to be executed by and amongst the Company, the Issuer, the book running lead managers to the Offer (the "BRLMs") and other selling shareholders (the Offer Agreement"); (iv) the common engagement letter with the Issuer, the BRLMs and other selling shareholders; (v) the registrar agreement to be entered into with the registrar, the Issuer and other selling shareholders (the "Registrar Agreement"); (vi) the underwriting agreement to be executed by and amongst the underwriter, the Issuer, the Company, the other selling shareholders and certain other parties (the "Underwriting Agreement"); (vii) the cash escrow and sponsor bank agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the "Cash Escrow and Sponsor Bank Agreement"); (viii) the share escrow agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the "Share Escrow Agreement"); (ix) the syndicate agreement to be executed by and amongst the Issuer, the Company, the other selling shareholders and certain other parties (the "Syndicate Agreement"); and (x) any other document, including a consent letter for variations of the terms of the Class A Preference Shares held by us, or agreement to be executed in relation to the Issue (collectively, the "Transaction Documents"), be and are hereby approved;
- D. any one of Mrs. Adillah Ibrahim Balladin or Messrs. Santosh Gujadhur or Tej K. Gujadhur be authorised to: (i) determine the number of Equity Shares that will be offered by the Company in the offer for sale or the aggregate amount to be raised by the Company through its participation in the offer for sale in the IPO, (ii) negotiate, finalise, execute, sign and deliver in the name and on behalf of the Company: (a) the Transaction Documents, substantially in the form approved or with such amendments as may be deemed necessary or desirable; and (b) any other related documents, offer documents (including the red herring prospectus and prospectus), deeds, consent letter, certificates, contracts, arrangements, and/ or ancillary documents, in relation thereto; (iii) finalise the offer price, the price band, discount (if any), the anchor allocation and any other offer terms in relation to the Issue, along with the Issuer in consultation with the book running lead managers appointed for the Issue and (iv) take all actions as may be required or necessary in the context of the Issue and any other matters in connection therewith;
- E. any and all actions of the Company, or of any director or officer or advisor, taken in connection with the actions contemplated by the foregoing prior to the execution hereof be ratified, confirmed, approved and adopted in all respects as fully as if such action(s) had been presented for approval, and approved by, all directors prior to such action being taken;

F. in connection with the actions contemplated by the foregoing resolutions, each of the directors, officers and any attorney or authorised signatory and such other person as were authorised by any of them be authorised, in the name and on behalf of the Company, to do such further acts and things as any director or officer or such duly authorised other person shall deem necessary or appropriate in connection with, or to carry out the actions contemplated by, the foregoing resolutions, including to do and perform (or cause to be done and performed), in the name and on behalf of the Company, all such acts and to make, execute, deliver, issue or file (or cause to be made, delivered, or filed) with any person including any governmental authority or agency, all such agreements, documents, instruments, certificates, consents and waivers, and all amendments to any such agreement, documents, instruments, certificates, and to pay, or cause to be paid, all such payments, as any of them may deem necessary or advisable to carry out the intent of the foregoing resolutions, the authority for the taking of any such action and the execution and delivery of such of the foregoing to be conclusively evidenced hereby."

IT IS HEREBY CERTIFIED THAT the above are true and correct extracts from the shareholders' resolutions of the company held on the date first mentioned above.

Dated this September 24, 2021



.....
Adilah Ibrahim Balladin
Apex Fund & Corporate Services (Mauritius) Ltd
Company Secretary



CONSENT FROM THE INDIVIDUAL SELLING SHAREHOLDER

To,

The Board of Directors
Global Health Limited
Medanta – Mediclinic
E-18, Defence Colony
New Delhi – 110024, India

Dear Sir,

Sub: Proposed initial public offering of equity shares (the “Equity Shares”) of Global Health Limited (the “Company” and such offer, the “Offer”)

I hereby give our consent to the following:

- (i) Inclusion of up to 1,00,000 Equity Shares held by me jointly with Mrs. Suman Sachdeva in the Company as part of the Offer for sale in the offer (“Offered Shares”), subject to the approval of Securities and Exchange Board of India (“SEBI”), and of any other regulatory authority, if required.
- (ii) Inclusion of my name as an Individual Selling Shareholder and any other information as required under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and other applicable laws in the Red Herring Prospectus and the Prospectus to be filed by the Company with the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi (the “RoC”), SEBI and any relevant stock exchange(s) where the Equity Shares are proposed to be listed (the “Stock Exchanges”).

I also authorise you to deliver a copy of this letter of consent to the RoC, pursuant to the provisions of Sections 26 and 32 of the Companies Act, 2013, the Stock Exchanges, SEBI or any other statutory or regulatory authority, as required by law. I also consent to the inclusion of this letter as a part of “*Material Contracts and Documents for Inspection*” in connection with the Offer, which will be available to the public for inspection from the date of the filing of the RHP until the Bid/ Offer Closing Date.

I confirm that this consent will remain valid and in force till the date on which Equity Shares of the Company start trading on the Stock Exchanges, in the absence of any written communication from us.

I confirm that the information in this letter is true, correct, complete and adequate to enable investors to make a well-informed decision, and is in accordance with the requirements of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law, and there is no misleading statement or material omission which would render the contents of this certificate misleading in its form or context.

I confirm that I will immediately communicate any changes in writing in the above information to the Book Running Lead Managers until the date when the Equity Shares are listed and commence trading on the relevant stock exchanges (the “Stock Exchanges”) pursuant to the Offer. In the absence of any such communication from us, the Book Running Lead Managers and the legal advisors to each of the Company and Book Running Lead Managers can assume that there is no change to the above information until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Offer.

This letter is for information and for inclusion (in part or full) in the red herring prospectus (“RHP”) and the prospectus (“Prospectus”) filed in relation to the Offer (collectively, the “Offer Documents”) or any other Offer-related material, and may be relied upon by the Company, the Book Running Lead Managers and the legal advisors appointed by the Company and the Book Running Lead Managers in relation to the Offer. I hereby consent to this letter being disclosed

by the Book Running Lead Managers, if required (i) by reason of any law, regulation or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defence in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation. I hereby consent to the aforementioned details being included in the Offer Documents and submission of this letter as may be necessary, to the SEBI, the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi ("RoC"), the Stock Exchanges and any other regulatory or judicial authorities and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Offer Documents.

Thanking You

Yours faithfully,

SUNIL
SACHDEVA
Digitally signed by
SUNIL SACHDEVA
Date: 2022.10.11
18:48:59 +05'30'

Name: Mr. Sunil Sachdeva

Date: 11-10-2022

Cc:

Kotak Mahindra Capital Company Limited
1st Floor, 27 BKC, Plot No. 27, 'G' Block
Bandra Kurla Complex, Bandra (East), Mumbai 400 051
Maharashtra, India

Credit Suisse Securities (India) Private Limited
Ceejay House, 10th Floor, Plot F, Shivsagar Estate,
Dr. Maharashtra, India Annie Besant, Road, Worli,
Mumbai 400 018,

Jefferies India Private Limited
42/43, 2 North Avenue
Maker Maxity, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051
Maharashtra, India

JM Financial Limited
7th Floor, Cnergy,
Appasaheb Marathe Marg,
Prabhadevi, Mumbai 400 025

S&R Associates
64, Okhla Industrial Estate Phase III
New Delhi 110 020

AZB & Partners
AZB House
Plot No. A8, Sector-4
Noida 201 301

AZB & Partners
AZB House, Peninsula Corporate Park
Ganpatrao Kadam Marg, Lower Parel
Mumbai 400 013

CONSENT FROM THE INDIVIDUAL SELLING SHAREHOLDER

To,

The Board of Directors
Global Health Limited
Medanta – Mediclinic
E-18, Defence Colony
New Delhi – 110024, India

Dear Sir,

Sub: Proposed initial public offering of equity shares (the “Equity Shares”) of Global Health Limited (the “Company” and such offer, the “Offer”)

I hereby give our consent to the following:

- (i) Inclusion of up to 1,00,000 Equity Shares held by me jointly with Mr. Sunil Sachdeva in the Company as part of the Offer for sale in the offer (“Offered Shares”), subject to the approval of Securities and Exchange Board of India (“SEBI”), and of any other regulatory authority, if required.
- (ii) Inclusion of my name as an Individual Selling Shareholder and any other information as required under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and other applicable laws in the Red Herring Prospectus and the Prospectus to be filed by the Company with the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi (the “RoC”), SEBI and any relevant stock exchange(s) where the Equity Shares are proposed to be listed (the “Stock Exchanges”).

I also authorise you to deliver a copy of this letter of consent to the RoC, pursuant to the provisions of Sections 26 and 32 of the Companies Act, 2013, the Stock Exchanges, SEBI or any other statutory or regulatory authority, as required by law. I also consent to the inclusion of this letter as a part of “*Material Contracts and Documents for Inspection*” in connection with the Offer, which will be available to the public for inspection from the date of the filing of the RHP until the Bid/ Offer Closing Date.

I confirm that this consent will remain valid and in force till the date on which Equity Shares of the Company start trading on the Stock Exchanges, in the absence of any written communication from us.

I confirm that the information in this letter is true, correct, complete and adequate to enable investors to make a well-informed decision, and is in accordance with the requirements of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law, and there is no misleading statement or material omission which would render the contents of this certificate misleading in its form or context.

I confirm that I will immediately communicate any changes in writing in the above information to the Book Running Lead Managers until the date when the Equity Shares are listed and commence trading on the relevant stock exchanges (the “Stock Exchanges”) pursuant to the Offer. In the absence of any such communication from us, the Book Running Lead Managers, and the legal advisors to each of the Company and Book Running Lead Managers can assume that there is no change to the above information until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Offer.

**From: Suman Sachdeva
10/6, Vasant Vihar, New Delhi 110057**

This letter is for information and for inclusion (in part or full) in the red herring prospectus (“RHP”) and the prospectus (“Prospectus”) filed in relation to the Offer (collectively, the “Offer Documents”) or any other Offer-related material, and may be relied upon by the Company, the Book Running Lead Managers and the legal advisors appointed by the Company and the Book Running Lead Managers in relation to the Offer. I hereby consent to this letter being disclosed by the Book Running Lead Managers, if required (i) by reason of any law, regulation, or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defence in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation. I hereby consent to the aforementioned details being included in the Offer Documents and submission of this letter as may be necessary, to the SEBI, the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi (“RoC”), the Stock Exchanges and any other regulatory or judicial authorities and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Offer Documents.

Thanking You

Yours faithfully,

SUMAN Digitally signed by
SUMAN SACHDEVA
SACHDEVA Date: 2022.10.11
16:52:02 +05'30'

Name: Mrs. Suman Sachdeva

Date: 11-10-2022

Cc:

Kotak Mahindra Capital Company Limited
1st Floor, 27 BKC, Plot No. 27, 'G' Block
Bandra Kurla Complex, Bandra (East), Mumbai 400 051
Maharashtra, India

Credit Suisse Securities (India) Private Limited
Ceejay House, 10th Floor, Plot F, Shivsagar Estate,
Dr. Annie Besant Road, Worli,
Mumbai 400 018, Maharashtra, India


Jefferies India Private Limited
42/43, 2 North Avenue
Maker Maxity, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051
Maharashtra, India

JM Financial Limited
7th Floor, Cnergy,
Appasaheb Marathe Marg,
Prabhadevi, Mumbai 400 025

S&R Associates
64, Okhla Industrial Estate Phase III
New Delhi 110 020

AZB & Partners
AZB House
Plot No. A8, Sector-4
Noida 201 301

AZB & Partners
AZB House, Peninsula Corporate Park
Ganpatrao Kadam Marg, Lower Parel
Mumbai 400 013



S A S FININVEST LLP

LLPIN: AAA-0492

PAN: ADZFS9315E

Regd. Off.: A-10/6, Vasant

Vihar, New Delhi - 110057

Email: sas@sasgroup.in

CONSENT FROM S A S FININVEST LLP

To,
The Board of Directors
Global Health Limited
Medanta – Mediclinic
E-18, Defence Colony
New Delhi – 110024, India

Dear Sir,

Sub: Proposed initial public offering of equity shares (the “Equity Shares”) of Global Health Limited (the “Company” and such offer, the “Offer”)

We hereby give our consent to the following:


- (i) Inclusion of up to 1,00,000 Equity Shares held by us (in the capacity as beneficial owner) and by Mr. Sunil Sachdeva jointly along with Mrs. Suman Sachdeva (in their capacity as registered owners, collectively, referred as the “Individual Selling Shareholders”) in the Company as part of the offer for sale in the Offer (the “Offered Shares”), subject to the approval of the Securities and Exchange Board of India (“SEBI”), and of any other regulatory authority, if required. We also hereby confirm that Mr. Sunil Sachdeva and Mrs. Suman Sachdeva are authorized to undertake all actions and execute documents, undertakings, certificates in relation to the Offered Shares and the Offer, as may be required in their capacity as the Individual Selling Shareholders in the Offer.
- (ii) Inclusion of my name as an Individual Selling Shareholder and any other information as required under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and other applicable laws in the Red Herring Prospectus and the Prospectus to be filed by the Company with the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi (the “RoC”), SEBI and any relevant stock exchange(s) where the Equity Shares are proposed to be listed (the “Stock Exchanges”).

We also authorise you to deliver a copy of this letter of consent to the RoC, pursuant to the provisions of sections 26 and 32 of the Companies Act, 2013, the Stock Exchanges, SEBI or any other statutory or regulatory authority, as required by law. I also consent to the inclusion of this letter as a part of “*Material Contracts and Documents for Inspection*” in connection with the Offer, which will be available to the public for inspection from the date of the filing of the RHP until the Bid/ Offer Closing Date.

We confirm that this consent will remain valid and in force till the date on which Equity Shares of the Company start trading on the Stock Exchanges, in the absence of any written communication from us.

We confirm that the information in this letter is true, correct, complete and accurate and adequate to enable investors to make a well-informed decision, and is in accordance with the requirements of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law, and there is no untrue statement or omission which would render the contents of this letter misleading in its form or context.

We confirm that we will immediately communicate any changes in writing in the above information to the Book Running Lead Managers until the date when the Equity Shares are listed and commence trading on the relevant stock exchanges (the “Stock Exchanges”) pursuant to the Offer. In the absence of any such communication from us, the Book Running Lead Managers, and the legal advisors to each of the Company and Book Running Lead Managers can assume that there is no change to the above information until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Offer.



S A S FININVEST LLP
LLPIN: AAA-0492
PAN: ADZFS9315E

**Regd. Off.: A-10/6, Vasant
Vihar, New Delhi - 110057**
Email: sas@sasgroup.in

This letter is for information and for inclusion (in part or full) in the red herring prospectus ("RHP") and the prospectus ("Prospectus") filed in relation to the Offer (collectively, the "Offer Documents") or any other Offer-related material, and may be relied upon by the Company, the Book Running Lead Managers and the legal advisors appointed by the Company and the Book Running Lead Managers in relation to the Offer. We hereby consent to this letter being disclosed by the Book Running Lead Managers, if required (i) by reason of any law, regulation or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defence in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation. We hereby consent to the aforementioned details being included in the Offer Documents and submission of this letter as may be necessary, to the SEBI, the Registrar of Companies, National Capital Territory of Delhi & Haryana at Delhi ("RoC"), the Stock Exchanges and any other regulatory or judicial authorities and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law.

All capitalized terms used herein and not specifically defined shall have the same meaning as assigned to them in Offer Documents.

Thanking you

Yours faithfully,

For S A S Fininvest LLP

SUNIL	Digitally signed by SUNIL	SUMAN	Digitally signed by SUMAN
SACHDEV	SACHDEVA	SACHDE	SACHDEVA
A	Date: 2022.10.11 18:50:30 +05'30'	VA	Date: 2022.10.11 18:51:04 +05'30'

Name: Mr. Sunil Sachdeva and Mrs. Suman Sachdeva
Designation: Designated Partners of S A S Fininvest LLP
Date: 11-10-2022

Cc:

Kotak Mahindra Capital Company Limited
1st Floor, 27 BKC, Plot No. 27, 'G' Block
Bandra Kurla Complex, Bandra (East), Mumbai 400
051 Maharashtra, India

Credit Suisse Securities (India) Private Limited
Ceejay House, 10th Floor, Plot F, Shivsagar Estate,
Dr. Annie Besant Road, Worli,
Mumbai 400 018, Maharashtra, India

Jefferies India Private Limited
42/43, 2 North Avenue
Maker Maxity, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051
Maharashtra, India

JM Financial Limited
7th Floor, Cnergy,
Appasaheb Marathe Marg,
Prabhadevi, Mumbai 400 025

S&R Associates
64, Okhla Industrial Estate Phase III
New Delhi 110 020

AZB & Partners
AZB House
Plot No. A8, Sector-4
Noida 201 301

AZB & Partners
AZB House, Peninsula Corporate Park
Ganpatrao Kadam Marg, Lower Parel
Mumbai 400 013

2

Certified True Copy

